These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29622471)

  • 21. Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.
    Boye KS; Stein D; Matza LS; Jordan J; Yu R; Norrbacka K; Hassan SW; García-Pérez LE
    Drugs R D; 2019 Jun; 19(2):213-225. PubMed ID: 31115873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescription Patterns and Disease Control in Type 2 Diabetes Mellitus Patients in Nursing Home and Home Care Settings: A Retrospective Analysis in Germany.
    Kostev K; Rockel T; Jacob L
    J Diabetes Sci Technol; 2018 Jan; 12(1):136-139. PubMed ID: 28539088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
    Yurgin N; Secnik K; Lage MJ
    Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude.
    Wallace TM; Matthews DR
    QJM; 2000 Jun; 93(6):369-74. PubMed ID: 10873187
    [No Abstract]   [Full Text] [Related]  

  • 25. Using insulin in type 2 diabetes: in need of a renaissance?
    Kerr D; Olateju T
    J Diabetes Sci Technol; 2011 Jul; 5(4):829-33. PubMed ID: 21880221
    [No Abstract]   [Full Text] [Related]  

  • 26. HbA1c in the Evaluation of Diabetes Mellitus.
    O'Keeffe DT; Maraka S; Rizza RA
    JAMA; 2016 Feb; 315(6):605-6. PubMed ID: 26864415
    [No Abstract]   [Full Text] [Related]  

  • 27. HbAlc in an unselected population of 4438 people with type 2 diabetes in a Danish county.
    Kristensen JK; Bro F; Sandbaek A; Dahler-Eriksen K; Lassen JF; Lauritzen T
    Scand J Prim Health Care; 2001 Dec; 19(4):241-6. PubMed ID: 11822648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treat-to-target HbA
    Gagliardino JJ; Elgart J; Forti L; Guaita MS; Chantelot JM
    Diabetes Metab Res Rev; 2019 Sep; 35(6):e3166. PubMed ID: 30963685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualised targets for insulin initiation in type 2 diabetes mellitus-the influence of physician and practice: a cross-sectional study in eight European countries.
    Boels AM; Koning E; Vos RC; Khunti K; Rutten GE
    BMJ Open; 2019 Aug; 9(8):e032040. PubMed ID: 31455718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-Centered Guidelines for Geriatric Diabetes Care: Potential Missed Opportunities to Avoid Harm.
    McCreedy EM; Kane RL; Gollust SE; Shippee ND; Clark KD
    J Am Board Fam Med; 2018; 31(2):192-200. PubMed ID: 29535235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hospital readmission and emergency department use based on prescribing patterns in patients with severely uncontrolled type 2 diabetes mellitus.
    Lee PH; Franks AS; Barlow PB; Farland MZ
    Diabetes Technol Ther; 2014 Mar; 16(3):150-5. PubMed ID: 24224752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America.
    Lopez Stewart G; Tambascia M; Rosas Guzmán J; Etchegoyen F; Ortega Carrión J; Artemenko S
    Rev Panam Salud Publica; 2007 Jul; 22(1):12-20. PubMed ID: 17931483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis.
    Filion KB; Joseph L; Boivin JF; Suissa S; Brophy JM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):973-6. PubMed ID: 19621344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The right drug at the right dose (how doctors decide what to prescribe).
    Marino MT
    Diabetes Self Manag; 2011; 28(2):8, 10-2, 14. PubMed ID: 21510246
    [No Abstract]   [Full Text] [Related]  

  • 35. Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.
    Wilding J; Bailey C; Rigney U; Blak B; Kok M; Emmas C
    Prim Care Diabetes; 2017 Oct; 11(5):437-444. PubMed ID: 28583425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variation in Point-of-Care Testing of HbA1c in Diabetes Care in General Practice.
    Kristensen T; Waldorff FB; Nexøe J; Skovsgaard CV; Olsen KR
    Int J Environ Res Public Health; 2017 Nov; 14(11):. PubMed ID: 29120361
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment.
    Mata-Cases M; Franch-Nadal J; Real J; Gratacòs M; López-Simarro F; Khunti K; Mauricio D
    Diabetes Obes Metab; 2018 Jan; 20(1):103-112. PubMed ID: 28656746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A National Survey of Physicians' Views on the Importance and Implementation of Deintensifying Diabetes Medications.
    Pilla SJ; Jalalzai R; Tang O; Schoenborn NL; Boyd CM; Bancks MP; Mathioudakis NN; Maruthur NM
    J Gen Intern Med; 2024 May; 39(6):992-1001. PubMed ID: 37940754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of English general practice level data linking medication levels, service activity and demography to levels of glycaemic control being achieved in type 2 diabetes to improve clinical practice and patient outcomes.
    Heald A; Davies M; Stedman M; Livingston M; Lunt M; Fryer A; Gadsby R
    BMJ Open; 2019 Sep; 9(9):e028278. PubMed ID: 31494602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increase in glycated haemoglobin concentrations after unwarranted prescription changes.
    Bell DSH; Goncalves E
    Diabetes Obes Metab; 2018 Oct; 20(10):2510-2511. PubMed ID: 29885012
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.